HZ-L105 shows potential against Bcl-2-dependent and venetoclax-resistant hematological cancers

Dec. 21, 2022

Researchers from Hangzhou Healzen Therapeutics Co. Ltd. and Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a next-generation Bcl-2 inhibitor, HZ-L105, being developed for the treatment of hematological cancers.

BioWorld Science Conferences New compound Cancer

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for February 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...